<?xml version='1.0' encoding='utf-8'?>
<document id="16531630"><sentence text="Influence of simvastatin at high dose and nifedipine on hemodynamic parameters in rabbits."><entity charOffset="13-24" id="DDI-PubMed.16531630.s1.e0" text="simvastatin" /><entity charOffset="42-52" id="DDI-PubMed.16531630.s1.e1" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.16531630.s1.e0" e2="DDI-PubMed.16531630.s1.e0" /><pair ddi="false" e1="DDI-PubMed.16531630.s1.e0" e2="DDI-PubMed.16531630.s1.e1" /></sentence><sentence text="Recent findings in vitro have shown that statins could reduce cardiomyocyte viability" /><sentence text=" The correlation between statin cardiotoxicity, assessed in vitro, and cardiac efficiency, investigated in vivo has not been estimated so far" /><sentence text=" The aim of the present experiment was to establish the impact of high-dose simvastatin on the hemodynamic parameters, especially on myocardium efficiency, after continuous infusion of dopamine"><entity charOffset="76-87" id="DDI-PubMed.16531630.s4.e0" text="simvastatin" /><entity charOffset="185-193" id="DDI-PubMed.16531630.s4.e1" text="dopamine" /><pair ddi="false" e1="DDI-PubMed.16531630.s4.e0" e2="DDI-PubMed.16531630.s4.e0" /><pair ddi="false" e1="DDI-PubMed.16531630.s4.e0" e2="DDI-PubMed.16531630.s4.e1" /></sentence><sentence text=" Moreover, hemodynamic interaction between simvastatin and nifedipine, metabolized by the same izoenzyme CYP3A4 was examined"><entity charOffset="43-54" id="DDI-PubMed.16531630.s5.e0" text="simvastatin" /><entity charOffset="59-69" id="DDI-PubMed.16531630.s5.e1" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.16531630.s5.e0" e2="DDI-PubMed.16531630.s5.e0" /><pair ddi="false" e1="DDI-PubMed.16531630.s5.e0" e2="DDI-PubMed.16531630.s5.e1" /></sentence><sentence text=" The experiments were performed on twenty seven New Zealand white rabbits" /><sentence text=" The animals were divided into four groups receiving: 0" /><sentence text="2% methylcellulose (MC) (control group), nifedipine, simvastatin or simvastatin + nifedipine, for 14 days (p"><entity charOffset="41-51" id="DDI-PubMed.16531630.s8.e0" text="nifedipine" /><entity charOffset="53-64" id="DDI-PubMed.16531630.s8.e1" text="simvastatin" /><entity charOffset="68-92" id="DDI-PubMed.16531630.s8.e2" text="simvastatin + nifedipine" /><pair ddi="false" e1="DDI-PubMed.16531630.s8.e0" e2="DDI-PubMed.16531630.s8.e0" /><pair ddi="false" e1="DDI-PubMed.16531630.s8.e0" e2="DDI-PubMed.16531630.s8.e1" /><pair ddi="false" e1="DDI-PubMed.16531630.s8.e0" e2="DDI-PubMed.16531630.s8.e2" /><pair ddi="false" e1="DDI-PubMed.16531630.s8.e1" e2="DDI-PubMed.16531630.s8.e1" /><pair ddi="false" e1="DDI-PubMed.16531630.s8.e1" e2="DDI-PubMed.16531630.s8.e2" /></sentence><sentence text="o" /><sentence text=")" /><sentence text=" The following hemodynamic parameters were estimated: cardiac output index (COI), heart rate (HR), systolic blood pressure (SBP), mean blood pressure (MBP), diastolic blood pressure (DBP) and total peripheral resistance index (TPRI)" /><sentence text=" The registration of hemodynamic parameters was performed by Doppler method (Hugo Sachs Electronic Haemodyn)" /><sentence text=" Dopamine did not cause a statistically significant increase in COI in rabbits receiving simvastatin alone or concomitantly with nifedipine"><entity charOffset="1-9" id="DDI-PubMed.16531630.s13.e0" text="Dopamine" /><entity charOffset="89-100" id="DDI-PubMed.16531630.s13.e1" text="simvastatin" /><entity charOffset="129-139" id="DDI-PubMed.16531630.s13.e2" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.16531630.s13.e0" e2="DDI-PubMed.16531630.s13.e0" /><pair ddi="false" e1="DDI-PubMed.16531630.s13.e0" e2="DDI-PubMed.16531630.s13.e1" /><pair ddi="false" e1="DDI-PubMed.16531630.s13.e0" e2="DDI-PubMed.16531630.s13.e2" /><pair ddi="false" e1="DDI-PubMed.16531630.s13.e1" e2="DDI-PubMed.16531630.s13.e1" /><pair ddi="false" e1="DDI-PubMed.16531630.s13.e1" e2="DDI-PubMed.16531630.s13.e2" /></sentence><sentence text=" Nifedipine significantly lowered COI, BP and HR in rabbits if given simultaneously with simvastatin"><entity charOffset="1-11" id="DDI-PubMed.16531630.s14.e0" text="Nifedipine" /><entity charOffset="34-37" id="DDI-PubMed.16531630.s14.e1" text="COI" /><entity charOffset="46-48" id="DDI-PubMed.16531630.s14.e2" text="HR" /><entity charOffset="89-100" id="DDI-PubMed.16531630.s14.e3" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.16531630.s14.e0" e2="DDI-PubMed.16531630.s14.e0" /><pair ddi="false" e1="DDI-PubMed.16531630.s14.e0" e2="DDI-PubMed.16531630.s14.e1" /><pair ddi="false" e1="DDI-PubMed.16531630.s14.e0" e2="DDI-PubMed.16531630.s14.e2" /><pair ddi="false" e1="DDI-PubMed.16531630.s14.e0" e2="DDI-PubMed.16531630.s14.e3" /><pair ddi="false" e1="DDI-PubMed.16531630.s14.e1" e2="DDI-PubMed.16531630.s14.e1" /><pair ddi="false" e1="DDI-PubMed.16531630.s14.e1" e2="DDI-PubMed.16531630.s14.e2" /><pair ddi="false" e1="DDI-PubMed.16531630.s14.e1" e2="DDI-PubMed.16531630.s14.e3" /><pair ddi="false" e1="DDI-PubMed.16531630.s14.e2" e2="DDI-PubMed.16531630.s14.e2" /><pair ddi="false" e1="DDI-PubMed.16531630.s14.e2" e2="DDI-PubMed.16531630.s14.e3" /></sentence><sentence text=" In conclusion, administration of nifedipine may elicit detrimental impact on statin therapy, resulting in the worsening of cardiac performance"><entity charOffset="34-44" id="DDI-PubMed.16531630.s15.e0" text="nifedipine" /></sentence><sentence text=" This may suggest another mechanism of drug-drug interaction than the one based on CYP3A4 inhibition" /><sentence text="" /></document>